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Dent disease is an X-linked renal proximal tubulopathy associated with mutations in the chloride channel gene
CLCN5. Lowe syndrome, a multisystem disease characterized by renal tubulopathy, congenital cataracts, and mental
retardation, is associated with mutations in the gene OCRL1, which encodes a phosphatidylinositol 4,5-bisphosphate
(PIP2) 5-phosphatase. Genetic heterogeneity has been suspected in Dent disease, but no other gene for Dent disease
has been reported. We studied male probands in 13 families, all of whom met strict criteria for Dent disease but
lacked mutations in CLCN5. Linkage analysis in the one large family localized the gene to a candidate region at
Xq25-Xq27.1. Sequencing of candidate genes revealed a mutation in the OCRL1 gene. Of the 13 families studied,
OCRL1 mutations were found in 5. PIP2 5-phosphatase activity was markedly reduced in skin fibroblasts cultured
from the probands of these five families, and protein expression, measured by western blotting, was reduced or
absent. Slit-lamp examinations performed in childhood or adulthood for all five probands showed normal results.
Unlike patients with typical Lowe syndrome, none of these patients had metabolic acidosis. Three of the five
probands had mild mental retardation, whereas two had no developmental delay or behavioral disturbance. These
findings demonstrate that mutations in OCRL1 can occur with the isolated renal phenotype of Dent disease in
patients lacking the cataracts, renal tubular acidosis, and neurological abnormalities that are characteristic of Lowe
syndrome. This observation confirms genetic heterogeneity in Dent disease and demonstrates more-extensive phe-
notypic heterogeneity in Lowe syndrome than was previously appreciated. It establishes that the diagnostic criteria
for disorders resulting from mutations in the Lowe syndrome gene OCRL1 need to be revised.
Introduction
Dent disease (MIM 300009) is an X-linked disorder of
renal tubular epithelial function, in which all of the
clinical findings may be traced to impaired reabsorption
of filtered solutes. Characteristic abnormalities include
low-molecular-weight (LMW) proteinuria and other fea-
tures of Fanconi syndrome, such as glycosuria, amino-
aciduria, and phosphaturia, but typically do not include
proximal renal tubular acidosis. Progressive renal failure
is common, as are nephrocalcinosis and kidney stones.
No extrarenal manifestations have been recognized—
except for rickets, in a minority of patients—and this
may be a consequence of hypophosphatemia from renal
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losses (Frymoyer et al. 1991; Wrong et al. 1994; Schein-
man and Thakker 2000).
Mutations in the CLCN5 gene encoding the renal
chloride channel CLC-5 have been reported consistently
in patients with Dent disease (Lloyd et al. 1996). This
CLC-5 chloride channel is believed to be critical to acid-
ification of endosomes that participate in solute reab-
sorption and membrane recycling in the proximal tubule
(Lloyd et al. 1996), and it is known to alter membrane
trafficking and the megalin-cubulin endocytic pathway.
Disruption of the mouse homolog of this gene produces
a phenotype resembling the human disease, confirming
the role of this gene in the human syndrome (Piwon et
al. 2000; Wang et al. 2000). A total of 68 distinct mu-
tations have been reported in 90 families with Dent
disease (Hoopes et al. 2004). However, we recently re-
ported 13 additional families with Dent disease in
whom mutations in CLCN5 were excluded, indicating
genetic heterogeneity (Hoopes et al. 2004). We now
describe mutations in another gene involved in proximal
tubular function that account for disease in 5 of these
13 families.
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Subjects and Methods
Patients
We studied the 13 probands reported by Hoopes et
al. (2004), all of whom met strict criteria for Dent disease
but lacked mutations in CLCN5. Details of patient iden-
tification and inclusion and exclusion criteria were de-
scribed in the previous study (Hoopes et al. 2004). All
affected males had LMW proteinuria, hypercalciuria,
and at least one of the following abnormalities: ne-
phrocalcinosis, nephrolithiasis, hematuria, hypophos-
phatemia, and renal insufficiency. Probands are identi-
fied using the family numbers assigned in the previous
study (Hoopes et al. 2004); the 19 families with muta-
tions in CLCN5 were numbered 1–19, and the 13 fam-
ilies without mutations were numbered 20–32. One fam-
ily was large enough to allow for linkage analysis. In
probands found to have mutations in OCRL1, slit-lamp
examination was performed. Studies were approved by
the Institutional Review Board for the Protection of Hu-
man Subjects at the SUNY Upstate Medical University,
and informed consent was obtained in compliance with
this approved protocol at all participating institutions.
Linkage Analysis
DNA was isolated from peripheral blood by use of a
standard protocol (Invitrogen) and was amplified using
GoTaq DNA Polymerase (Promega) under standard am-
plification conditions. Because the inheritance pattern in
this pedigree appeared to be X-linked, we studied mark-
ers on the X chromosome. PCR amplifications, per-
formed using primers flanking previously identified X-
chromosome–linked microsatellite markers (Research
Genetics), were run on 8% polyacrylamide gels and were
silver-stained, as described elsewhere (Shrimpton et al.
1999). Microsatellite markers were initially selected on
the basis of their heterozygosity and spacing approxi-
mately every 10 cM along the X chromosome. Addi-
tional microsatellite markers were subsequently selected
to refine the critical region. Linkage analysis was per-
formed using MLINK software, under the assumptions
of full penetrance in males, no penetrance in females,
frequency of disease alleles of 0.0001, male mutation
rate of 0.0, female mutation rate of 0.000001, and nine
alleles of equal frequency.
Mutation Detection
We used intronic primers to amplify the exons and
the intron/exon boundaries of candidate genes in the
critical linkage region. PCR was performed under stan-
dard conditions, by use of genomic DNA isolated from
blood leukocytes. PCR products were sequenced using
ABI BigDye 3.1 sequencing kits, on an ABI 3100-Avant
Genetic Analyzer. Both DNA strands were analyzed for
each exon, by use of Lasergene software from DNA-
STAR. Because the pedigree strongly suggested X link-
age, we sequenced CLCN4, which is a member of the
same family of chloride channel genes as CLCN5 and
is located at Xp22.3. We established linkage, however,
to a region at Xq25-Xq27.1 that included at least 65
genes. We evaluated those candidate genes on the basis
of putative function and information regarding ex-
pression in the kidney, and we sequenced first the
SLC9A6 gene, which encodes the NHE6 sodium-proton
exchanger, and next the OCRL1 gene. Sequences of the
primers used for sequencing CLCN4, SLC9A6, and
OCRL1 are listed in tables A1, A2, and A3 of appendix
A (online only).
Screening of Normal Populations for OCRL1 Mutations
To establish that the mutations we identified were not
common polymorphisms, we screened DNA represent-
ing 106–132 unrelated X chromosomes for each of the
mutations detected. Four of the mutations were screened
by restriction analysis. The exons affected by the mu-
tations were amplified by PCR, along with known nor-
mal DNA and that of an individual containing the mu-
tation. The PCR products were diluted in the manu-
facturer’s buffer, which allowed the restriction enzyme
to digest the amplicons to completion. The products
were analyzed by agarose gel electrophoresis. For one
mutation (436insAA), a restriction endonuclease was
not available, and we used allele-specific PCR (Bottema
and Sommer 1993) to detect the mutation. A 5′-fluo-
rescent-labeled forward primer was designed to amplify
DNA containing the mutation, and another was de-
signed to amplify the normal DNA sequence. These were
combined with a common unlabeled reverse primer so
that there was always at least one PCR product in the
reactions. These PCR products were analyzed by an ABI
3100-Avant Genetic Analyzer. The two alleles could be
distinguished by both size and fluorescence emission.
The primers used for this mutation were 6-FAM-TGAA-
TTTGGACAAGAAAAT for the normal allele, VIC-
TGAATTTGGACAAGAAAAA for the mutation, and
TCACATGGGACTTACAT for the common reverse
primer.
Enzyme Assays and Western Blotting for the OCRL1
PIP2 5-Phosphatase in Patient Fibroblasts
Fibroblasts were cultured from skin biopsy specimens
taken from each of the probands and, in family 24, from
two affected brothers. Measurements of the OCRL1
PIP2 5-phosphatase activity for the OCRL1 protein were
performed in duplicate in one laboratory by S.F.S., as
described elsewhere (Suchy et al. 1995). Western blot
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analysis for the OCRL1 protein and b-tubulin was
done using anti-OCRL1 antibody (Olivos-Glander et al.
1995) and b-tubulin antibody (Abcam), as described
elsewhere (Olivos-Glander et al. 1995).
Results
Linkage Analysis
Family history of Dent disease was seen in a typical
X-linked pattern in the relatives of the proband in family
24, whereas all other probands were isolated cases. The
initial haplotype analysis in family 24 excluded the X
chromosome, except for the 27-cM region between the
microsatellite markers DXS1001 and DXS1205 on the
long arm at Xq24-Xq27.1. Additional markers refined
the critical region demonstrating linkage to the disease
to the 15-cM region between DXS8057 and DXS984
at Xq25-Xq27.1. This 16-Mb critical region formed a
haplotype shared by all affected males in this family.
None of the unaffected males had this haplotype, which
demonstrated a maximum two-point LOD score of 3.31
at 0 cM between the disease and DXS1192, under the
assumption of an X-linked recessive mode of inheri-
tance, by use of the MLINK software.
OCRL1 Mutations
The sequences of CLCN4 and SLC9A6 were normal.
Five distinct mutations in OCRL1 were identified in 5
of the 13 families (table 1), none of which have been
reported previously in patients with Lowe syndrome
(MIM 309000). Two of these were missense mutations
in which a base substitution predicted a single–amino
acid change in exons 11 and 14, in the PIP2 5-phospha-
tase domain of the OCRL1 protein, where many known
mutations map (see Lowe Syndrome Mutation Database
Web site). One of these, the mutation R301C in family
24, clearly segregated with the disease (fig. 1). The other
three mutations, an intronic acceptor splice-site muta-
tion, a 2-base insertion, and a 4-base deletion, are in
exons 5 or 7 or intron 7 and are predicted to result in
frameshifts and premature translational termination.
The only mutations previously described in exons 1–8,
which encode a region of the OCRL1 protein with no
known homology to other proteins, have involved mul-
tiexon deletions.
Functional Consequences of the Mutations
Enzyme activity of the OCRL1 PIP2 5-phosphatase
was substantially reduced in skin fibroblasts from all five
probands to the range typically seen in patients with
Lowe syndrome (table 1). Enzyme activity was slightly
less reduced in the two families with missense mutations
(families 20 and 24) than in the three with truncating
mutations and no detectable OCRL1 protein. By western
blot analysis, protein was detectable at a reduced level
in the two families with missense mutations but was
undetectable in the other three families, consistent with
the nature of the mutations (table 1 and fig. 2).
Both missense mutations would be expected to alter
function. The Y462C mutation in exon 14 substitutes
cysteine for tyrosine, an aromatic amino acid residue
within the PTYKYD domain that is highly conserved
among all known phosphoinositide 5-phosphatases. The
R301C mutation inserts a cysteine in the place of a
highly basic residue, arginine, in exon 11 (this residue
is either arginine or glutamine in the highly related phos-
phatidylinositol and inositol 5-phosphatases INPP5B,
PIB5PA, synaptojanin, and INPPL1).
Clinical Features
Slit-lamp examinations showed normal results in all
five probands. None had the characteristic facial ap-
pearance of patients with Lowe syndrome, although one
patient was thought to be borderline dysmorphic be-
cause of a narrow skull without scaphocephaly, asym-
metric ears, and a suggestion of periorbital fullness. Slit-
lamp examinations of an affected sibling of the proband
in family 24 and the parents of the proband in family
20 showed normal results. Formal mental-developmen-
tal testing was performed for four of the five probands.
In three, there was evidence of mild developmental delay.
The proband in family 24 showed mild mental retar-
dation when tested by MAWI (Magyar Wechsler Intel-
ligencia Teszt) (IQ 80; VQ 87; PQ 76), as did his brother
(IQ 67; VQ 70; PQ 70); the proband in family 20 also
showed mild mental retardation when tested by HA-
WIK-R (Hamburg-Wechsler Intelligence Test for Kinder-
Revised) (IQ 83; verbal 82; action 87). In these tests,
scores between 80 and 90 are considered low average,
and those between 70 and 80 are considered to reflect
borderline mental retardation. The proband in family
20 was also tested by CFT-2 (Cattell Culture Fair Test-
2), for which his score was normal (IQ 95). The proband
in family 29 had reduced scores by BHTHM testing
(VIQ 72; MIQ 57; GIQ 62). The patient in family 25
was normal by the Kaufmann Assessment Battery for
Children (60%) and Raven’s Colored Progressive Ma-
trices (63%). The proband in family 26 was not tested
formally but is an honor student enrolled in regular
school. It is worth noting that the two patients with
normal intelligence, as assessed by history or by devel-
opmental testing (patients in families 25 and 26), had a
deficiency of the OCRL1 PIP2 5-phosphatase as pro-
found as that seen in patients with classical Lowe syn-
drome and showed no protein by western blotting.
In contrast to the typical patient with Lowe syndrome,
none of the affected males in these families required ther-
apy with bicarbonate. Four of the five were able to acid-
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Figure 1 Segregation of the R301C mutation in family 24. The pedigree is shown, with affected subjects identified as blackened symbols.
Digestion of the 298-bp exon 11 amplicons with the restriction endonuclease HhaI in normal subjects results in two products of 158 bp and
140 bp (subjects IV:1, II:3, II:4, and III:8). The mutated sequence produces a single detectable digest of 298 bp (subjects IV:2, II:5, III:4, III:5,
III:6, and III:7). Heterozygous females display all three products (subjects III:2, III:3, II:7, and II:8). The lane containing PhiX174/HaeIII
molecular weight markers is indicated by “M.”
ify urine to !pH 5.8, either on acid loading or on a first-
morning voided specimen; a test of urine acidification
was not available for the fifth patient. Only one of the
patients had growth retardation, which was mild, and
that patient was able to acidify urine to !pH 5.5 on
ammonium chloride loading.
None of the patients had nephrolithiasis, and only one
of the five probands had nephrocalcinosis on ultrasound
examination. None had clinical rickets, although one
had mildly reduced bone mineral density. As is com-
monly seen in Dent disease, Fanconi syndrome was in-
complete in these patients. Three of the five had inap-
propriate urinary phosphate loss with hypophospha-
temia. Two had aminoaciduria; none had glycosuria.
Although the prevalence of some of these features was
higher in the 19 probands with CLCN5 mutations in
our recent study describing genetic heterogeneity in Dent
disease (Hoopes et al. 2004) and in previously published
studies (Scheinman 1998; Scheinman and Thakker
2000), the number of cases in the present study is too
small to allow any statistical comparisons.
Two of the probands had mild elevations in muscle
enzymes, although without muscle weakness. These pa-
tients (from families 20 and 29) had elevations of cre-
atine kinase, aspartate aminotransferase, alanine ami-
notransferase, and lactate dehydrogenase that were 1.1–
2.0-fold elevated above the upper limit of normal, but
there was no clinical evidence of muscle weakness. Mild
elevations in muscle enzymes have been described in pa-
tients with Lowe syndrome (Charnas et al. 1991).
Discussion
Of the 32 families with the clinical diagnosis of Dent
disease reported by Hoopes et al. (2004), 19 (60%) had
mutations in CLCN5. We have now demonstrated that
another five (16%) have mutations in OCRL1, in pa-
tients for whom the diagnosis of Lowe syndrome had
been excluded because cataracts were absent. Since these
two genes do not account for all patients with the phe-
notype of Dent disease, it is likely that other genes in-
volved in proximal tubular function will be found to be
mutated in such patients. This appears analogous to an-
other inherited renal tubulopathy, Bartter syndrome, for
which there are now five genes known to be responsible
in subgroups of patients (Vargas-Poussou et al. 2002).
Although it is formally possible that some of the pa-
tients described here had the relatively mild phenotype
of Dent disease, despite having mutations in the OCRL1
gene (because of somatic mosaicism of their OCRL1
mutations), there are three lines of evidence that argue
against this explanation. First, the mutations were seen
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Figure 2 Western blot analysis of OCRL1 in control and patient
fibroblasts. Fibroblast supernatant (20 mg), which was prepared as
described in the text, was loaded in each lane. Lane 1, a Lowe syn-
drome patient known to not express OCRL1; lane 2, an unaffected
individual (control fibroblasts); lane 3, proband from family 25; lane
4, proband from family 20; lane 5, proband from family 29; lane 6,
proband from family 26; and lanes 7 and 8, two affected brothers
from family 24. The positions and sizes of broad-range protein markers
(Bio-Rad) are shown on the left. The presence of adequate protein
loading in all lanes is demonstrated in the lower panel by a western
blot analysis of the same blot with the use of antibody against b-
tubulin as a control.
clearly in the sequences of PCR products made from
DNA extracted from white blood cells, without any
evidence of admixture of normal and mutant gene se-
quence. Second, the enzyme assays and western blotting
were both performed on cultured fibroblasts, a different
tissue, with clear evidence of deficient enzyme activity
and, in some cases, absent protein. Thus, if somatic
mosaicism were present, it would have to be absent in
two independently derived tissues, white blood cells and
skin fibroblasts. Finally, the evidence of multiple af-
fected individuals in family 24 argues against mosai-
cism, at least in this one family.
Both Dent disease and Lowe oculocerebrorenal syn-
drome involve disordered proximal tubular function,
and their clinical renal findings are similar but not iden-
tical. Both are associated with extreme degrees of LMW
proteinuria (Norden et al. 2001), as well as other fea-
tures of proximal tubular reabsorptive failure, such as
renal glycosuria, aminoaciduria, and phosphaturia. Re-
nal failure is common in both (Charnas et al. 1991;
Frymoyer et al. 1991; Wrong et al. 1994; Scheinman
and Thakker 2000). Hypercalciuria, nephrocalcinosis,
and nephrolithiasis—common features of Dent dis-
ease—have been reported, but only rarely, in patients
with Lowe syndrome (Sliman et al. 1995). In these five
families, hypercalciuria was present in all five probands,
nephrocalcinosis was present in only one proband, and
none of the probands had kidney stones. Two of the
five probands had some degree of reduction in glome-
rular filtration rate.
Renal tubular acidosis is a prominent feature of Lowe
syndrome, usually requiring alkali therapy to ameliorate
the growth retardation. In contrast, it is not a feature
of Dent disease (Scheinman 1998). Despite having mu-
tations in OCRL1, none of patients in these five families
had acidosis.
The predominant renal manifestation of both Lowe
syndrome and Dent disease is Fanconi syndrome, par-
ticularly LMW proteinuria but also other abnormalities
in proximal tubular reabsorption, such as renal wasting
of phosphate and amino acids. The ClC-5 chloride
channel is located in subapical endosomes that are crit-
ical to the process of degradation of reabsorbed proteins
by the proximal tubular epithelium. Mutations that im-
pair chloride flow through this channel lead to impaired
acidification of the endosomal lumen, and, as a con-
sequence, trafficking of endosomal membrane back to
the apical surface is disrupted (Christensen et al. 2003).
The role of OCRL1 mutations in causing Lowe syn-
drome is still unclear. Impaired function of the OCRL1
phosphatase leads to elevation in cellular levels of
PIP2—which is known to be involved in vesicle traf-
ficking at the Golgi apparatus, where OCRL1 is local-
ized (Dressman et al. 2000)—but a defect in Golgi traf-
ficking has yet to be demonstrated in Lowe syndrome.
Elevated PIP2 levels are also believed to be responsible
for the alterations in the actin cytoskeleton observed in
fibroblasts from patients with Lowe syndrome (Suchy
and Nussbaum 2002). Actin remodeling is closely con-
nected to both Golgi trafficking (Randazzo and Hirsch
2004) and endosomal membrane trafficking (Apodaca
2001), which suggests that abnormalities in the actin
cytoskeleton could act on a number of cellular processes
in the renal epithelium of patients with Lowe syndrome.
Although phenotypic variability in the renal and neu-
rological phenotypes is a well-known feature of Lowe
syndrome, dense congenital cataracts are considered a
cardinal finding required for diagnosis. They are always
present at birth and can be found at 20–24 wk of ges-
tation (Charnas and Nussbaum 2001). Cataracts, usu-
ally clinically insignificant, are consistently present even
in carrier females and are used as a screening method
for the carrier state (Roschinger et al. 2000). The present
findings demonstrate that the absence of cataracts does
not exclude the possibility of mutations in OCRL1. The
lack of cataracts in the affected members of family 24
suggests further that this particular mutation, R301C,
may be an allele that causes renal disease only, although
a modifier gene closely linked to the OCRL1 locus can-
not be ruled out. In contrast, three of the patients re-
ported here have deficient OCRL1 PIP2 5-phosphatase
activity and complete absence of the OCRL1 protein by
western blotting—results that are indistinguishable
from those seen in classic Lowe syndrome with dense
cataracts. However, all three patients lacked cataracts,
and two patients had no detectable mental retardation.
These results indicate that the variability in Lowe syn-
drome cannot be entirely due to allelic differences in
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the OCRL1 gene itself; instead, these results more likely
point to modifying loci and/or unknown environmental
factors that can significantly alter the phenotypic con-
sequences of a deficiency of the OCRL1 protein.
OCRL1 encodes a PIP2 5-phosphatase that is widely
distributed in human tissues, so it is not clear why de-
ficiency of this enzyme results in a phenotype that is
specific to the eye, brain, and kidney. A clue to the
answer may come from studies of a mouse model of
PIP2 5-phosphatase deficiency. Knockout mice in which
expression of the Ocrl1 gene is prevented by targeted
disruption have no evidence of cataracts, neurological
abnormalities, or renal dysfunction. However, simul-
taneous deficiency of both Ocrl1 and another phos-
phatase gene that is highly homologous to Ocrl1
(Inpp5b) results in an embryonic lethal phenotype. This
strongly suggests that the Inpp5b phosphatase can com-
pensate for absence of the Ocrl1 enzyme. If the same
or a similar phenomenon occurs in humans and if there
is variability among tissues and individuals in the ex-
pression of the compensating enzyme, then this could
explain the phenotypic variability, such as the absence
of cataracts and the normal urinary acidifying ability,
in some patients with OCRL1 mutations (Janne et al.
1998).
These findings demonstrate that Dent disease can be
caused by mutations at at least three loci and also that
not all mutations in the OCRL1 gene cause Lowe syn-
drome. Mutations in the OCRL1 gene cannot be ex-
cluded on the basis of the absence of cataracts in pa-
tients with Fanconi syndrome.
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